Neuroendocrine (NE)-like cells are hypothesized to contribute to the progression of prostate cancer by producing factors that enhance the growth, survival or metastatic capabilities of surrounding tumor cells. Many of the factors known to be secreted by NE-like cells, such as neurotensin (NT), parathyroid hormone-related peptide, serotonin, bombesin, etc., are agonists for G-proteincoupled receptors, but the signaling pathways activated by these agonists in prostate tumor cells are not fully defined. Identification of such pathways could provide insights into novel methods of treating late-stage disease. Using conditioned culture medium (CM) from LNCaPderived NE-like cells (as a source of these agonists) or NT (a prototypical component of CM) to treat PC3 cells, we found that the epidermal growth factor (EGF) receptor (EGFR) was transactivated and that such activation was required for maximal PC3 cell mitogenesis, as measured by 5-bromo-2 0 -deoxy-uridine incorporation or cell number. NT also induced a time-dependent increase in EGFR 
Introduction
Neuroendocrine (NE) differentiation has gained increasing interest as a likely mechanism contributing to prostate cancer progression. Multiple lines of evidence support the idea that malignant prostate cells can differentiate into NE-like cells, both in vitro and in vivo (Amorino and Parsons, 2004) . These NE-like cells are hypothesized to be involved in the development of advanced disease by secreting growth, survival and migratory factors for surrounding tumor cells (di Sant'Agnese, 1992; Abrahamsson, 1999; Amorino and Parsons, 2004) . A large number of clinical studies have demonstrated that prostatic NE cells and their associated markers serve as prognostic indicators of tumor progression and patient survival (di Sant'Agnese, 1992; Abrahamsson, 1999; Amorino and Parsons, 2004) . Thus, NE cells may be involved in the etiology of prostate cancer.
Although the mechanisms controlling in vivo differentiation of prostatic NE cells are only partially understood, we and others have previously demonstrated acquisition of NE characteristics by stimulating prostate cancer cell lines in vitro with various agents that are naturally present in the tumor microenvironment, such as interleukin-6 and epinephrine (Deeble et al., 2001; Amorino and Parsons, 2004) . LNCaP cells acquire NE characteristics in response to androgen withdrawal, IL-6 addition and/or treatment with physiological and pharmacological agents that elevate intracellular cyclic adenosine monophosphate (cAMP), such as epinephrine, isoproterenol, forskolin and dibutyryl cAMP (Qiu et al., 1998; Cox et al., 1999 Cox et al., , 2000 Deeble et al., 2001) . Removal of differentiating agents results in reversion to the tumor cell phenotype, indicating that the process is reversible. Differentiation in response to cAMP-elevating agents also results in protein kinase A (PKA) activation (Deeble et al., 2001) . Overexpression of the PKA catalytic subunit is sufficient to induce NE differentiation in LNCaP cells, and NE differentiation is inhibited by the expression of a dominant-negative (DN) mutant of the PKA regulatory subunit (Cox et al., 2000) . NE-like cells derived from LNCaP cells are nonmitotic and secrete significantly greater amounts of the mitogenic neuropeptides, parathyroid hormone-related peptide (PTHrP) and neurotensin (NT) Deeble et al., 2001) , relative to undifferentiated parental LNCaP cells.
Several studies have demonstrated the in vitro growth modulation of prostate cancer cells by neuropeptides, which are known to be secreted by prostatic NE-like cells. Bombesin and calcitonin each exert a proliferative effect on the androgen-independent PC-3 and DU-145 prostate cancer cell lines (Bologna et al., 1989; Jongsma et al., 2000; Larran et al., 2000) , as well as stimulation of PC3 cell migration (Aprikian et al., 1997) . Cell growth and DNA synthesis are increased when prostate cancer cells are stimulated with PTHrP (Iwamura et al., 1994; Tovar-Sepulveda and Falzon, 2002) . Proliferation and DNA synthesis of PC3 cells (Seethalakshmi et al., 1997; Lee et al., 2001; Hassan and Carraway, 2006) , and also of LNCaP cells in the absence of androgen (Sehgal et al., 1994; Lee et al., 2001) , are stimulated when cells are treated with NT. Receptors for bombesin (Reile et al., 1994; Aprikian et al., 1996; Xiao et al., 2002) , NT (Seethalakshmi et al., 1997; Dal Farra et al., 2001; Petit et al., 2001) and PTHrP (Tovar-Sepulveda and Falzon, 2002) are expressed by PC3, LNCaP and/or DU145 prostate cancer cells and have been characterized with respect to proliferative function. Thus, mitogenic neuropeptides that are secreted by NE-like cells can activate specific membrane-bound receptors on the surface of prostate cancer cells, resulting in increased proliferation and DNA synthesis. However, the molecular pathways by which neuropeptides stimulate mitogenesis are only partially understood, and a more complete description of these pathways is needed to identify new candidates for therapeutic intervention.
Neuropeptides, such as NT, bombesin and PTHrP, bind G-protein-coupled receptors (GPCRs). Numerous, recent reports have shown that transactivation of the epidermal growth factor (EGF) receptor (EGFR) is critical for the mitogenic activity of multiple GPCR agonists (Daub et al., 1996 (Daub et al., , 1997 Prenzel et al., 1999; Madarame et al., 2003; Xiao et al., 2003; Zhao et al., 2004) and that EGFR transactivation requires metalloproteinase (MMP) cleavage of pro-heparin-binding EGF-like growth factor (pro-HB-EGF) into HB-EGF, which is released from the cell surface to bind the EGFR in an autocrine or paracrine manner (Prenzel et al., 1999; Madarame et al., 2003; Santiskulvong and Rozengurt, 2003; Yano et al., 2004; Zhao et al., 2004; Hassan and Carraway, 2006) . However, the detailed signaling events following EGFR transactivation that are required for mitogenic activation are not fully understood, particularly in prostate cancer cells.
We have previously demonstrated that c-Src-mediated phosphorylation of EGFR Tyr 845 is critical for the mitogenic response to EGFR stimulation in human breast cancer cells and murine fibroblasts, even when other EGFR signaling pathways remain active Tice et al., 1999; Boerner et al., 2005) . As a result of these and other studies, phospho-Tyr 845 is emerging as a candidate, novel target of the EGFR, and efforts are underway to develop small molecule inhibitors of phospho-Tyr 845 , which will disrupt its interaction with its downstream effectors, for example, signal transducer and activator of transcription 5b (Stat5b) (Kloth et al., 2003) and cytochrome c oxidase subunit II (CoxII) (Boerner et al., 2004) . Importantly, roles for neither Tyr 845 nor Stat5b/CoxII in NE-related prostate cancer progression have been reported. Therefore, using secretions from NE-like cells or NT as an example of NE-like cell-derived neuropeptides, we examined the potential involvement of this pathway in NT-induced mitogenesis of human prostate cancer cells.
Results
Stimulation of PC3 proliferation and DNA synthesis by NE-like cells Recent evidence suggests that NE-like cells are involved in the progression of prostate cancer, through secretion of paracrine factors. We and others have previously shown that LNCaP cells undergo NE-like differentiation following treatment with epinephrine, forskolin or interleukin-6 (Qiu et al., 1998; Cox et al., 1999 Cox et al., , 2000 Deeble et al., 2001) and demonstrated that expression of a constitutively active form of the PKA catalytic subunit, Cqr, in LNCaP cells results in the acquisition of NE characteristics (Cox et al., 2000) . These NE-like cells secrete significantly greater amounts of NT and PTHrP than undifferentiated LNCaP cells . To test whether the secretions of NE-like cells (which contain multiple agonists of GPCRs) can stimulate PC3 proliferation and/or DNA synthesis via the EGFR, an LNCaP cell line (D29) was used that expresses a constitutively active PKA catalytic subunit (Cqr) via a doxycycline (dox)-inducible promoter ( Figure 1a ). PC3 cells incubated with conditioned medium (CM) from dox-treated D29 cells showed a significant increase (P ¼ 0.002) in proliferation (as measured by cell number) compared to cells incubated with CM from D29 cells without dox (Figure 1b ). This increase was partially but significantly (P ¼ 0.02) abrogated by treatment of PC3 cells with the EGFR-specific tyrphostin, AG1478 (Levitzki and Gazit, 1995) , for 60 min before and during incubation with D29 CM. PC3 cells incubated with CM from D29 cells expressing Cqr also showed a similar increase (P ¼ 0.02) in DNA synthesis 5-bromo-2 0 -deoxy-uridine (BrdU) incorporation compared to cells incubated with D29 CM without Cqr expression (data not shown), and this effect was also partially inhibited by AG1478. Treatment of PC3 cells with control non-CM containing dox did not stimulate proliferation (P ¼ 0.49). These results demonstrate that secretions from NE-like cells induce increases in proliferation and DNA synthesis in undifferentiated prostate cancer cells. The data also suggest that EGFR transactivation is involved in NE cell stimulation of PC3 growth, as AG1478 partially inhibited this effect.
NT-induced transactivation of the EGFR
We have previously shown that CM from LNCaPderived NE-like cells contains increased amounts of NT compared to CM from undifferentiated LNCaP Deeble et al., 2001) . Using NT as a prototype neuropeptide, and knowing that the NT receptor is a GPCR (Seethalakshmi et al., 1997), we hypothesized that NT secreted by NE-like cells can act upon prostate cancer cells to transactivate the EGFR as described in the Introduction (Daub et al., 1996 (Daub et al., , 1997 Prenzel et al., 1999) . To test this hypothesis, PC3 cells were pre-incubated with SR48692, a potent and selective non-peptide antagonist for the neurotensin receptor (NTR) (Gully et al., 1993) with specificity for NTR1 (Labbe-Jullie et al., 1998) . The PC3 cell mitogenesis induced by D29 CM was partially but significantly (Po0.05) blocked by SR48692 (Figure 1c) , suggesting that NT secretion by NE-like cells plays a role in prostate cancer cell growth.
To further test this hypothesis, PC3 cells were treated with various concentrations of NT for different time periods, and total EGFR tyrosine phosphorylation (p-Tyr) was measured by EGFR immunoprecipitation and Western blotting. Stimulation with NT at different concentrations and for different times resulted in a maximal mean increase in EGFR p-Tyr levels between fourfold and sixfold at 100 nM NT for 60 min (Figure 2a, b) ; no activation was observed at times earlier than 15 min. The NT-induced activation of EGFR was abrogated by pre-incubation of cells with the EGFR tyrosine kinase inhibitor, AG1478 (Figure 2c ). Thus, NT treatment results in the transactivation of the EGFR in PC3 prostate cancer cells.
EGFR Tyr
845 is activated by NT in a c-Src-dependent manner In breast cancer cells, Tyr 845 of the EGFR has been identified as a c-Src-dependent phosphorylation site that is required for cell proliferation by multiple agonists Boerner et al., 2004 Boerner et al., , 2005 . We therefore tested whether this phosphorylation site was involved in transactivation of the EGFR by NT in prostate cancer cells. As observed with total EGFR p-Tyr, maximal phosphorylation of EGFR Tyr 845 (3-6 fold increase) in PC3 cells was observed at 60 min posttreatment with 100 nM NT (Figure 3a) . To test the role of c-Src in this response, a specific chemical inhibitor of Src 4-amino-5-(4-chlorophenyl)-(t-butyl)pyrazolo [3,4-D] pyrimidine (PP2) was used. NT-induced phosphorylation of Tyr 845 was abrogated by pre-incubation of cells with either PP2 or AG1478 (Figure 3b ). The apparent increase in phospho-Tyr 845 with AG1478 treatment alone was not statistically significant. As matrix MMPs have been implicated in transactivation of the EGFR by GPCRs (Madarame et al., 2003; Santiskulvong and Rozengurt, 2003; Yano et al., 2004; Zhao et al., 2004; Hassan and Carraway, 2006) , a general inhibitor of MMPs, GM1006 (galardin), was used to test the role of MMPs (Santiskulvong and Rozengurt, 2003) . Pre-incubation of PC3 cells with GM1006 for 1 h before and during NT stimulation completely blocked the NTinduced increases in Tyr 845 phosphorylation ( Figure 3c ). NT treatment also resulted in a time-dependent activation of c-Src (measured as phosphorylation of its autophosphorylation site, tyrosine 419), which reached a maximum at 60 min ( Figure 4a ). Increased phosphorylation of c-Src upon NT treatment was Figure 1 Effect of NE cell secretions on proliferation of PC3 cells. LNCaP cells were generated (D29 clone) that express a doxinducible FLAG-tagged constitutively active PKA catalytic subunit (Cqr), conferring an NE phenotype. D29 cells were incubated with 2 mg/ml dox (or not) in serum-free medium for 5 days. PC3 cells were then treated (or not) with 500 nM AG1478 (EGFR inhibitor) or 100 nM SR48692 (NTR antagonist) for 1 h, incubated with D29 CM for 48 h (7AG1478 or SR48692), and subjected to proliferation analysis (cell counting). Error bars represent the standard error of the mean (s.e.m.) from three independent experiments. *Po0.05, relative to control; **Po0.05, relative to þ dox. Stimulation of proliferation and DNA synthesis by NT The EGFR activates downstream signaling pathways involved in cellular proliferation. Therefore, we tested whether NT would stimulate proliferation of prostate cancer cells. A time-dependent increase in proliferation was observed using 100 nM NT in both androgenindependent PC3 cells ( Figure 5a ) and androgenresponsive LNCaP cells ( Figure 5b ). The NT-induced increase in cell number was significantly greater (Po0.05) than untreated control at 24, 48 and 72 h after the addition of NT, although these increases were less than those induced by 10% fetal bovine serum (FBS). Incubation with 100 nM NT for 72 h did not cause any significant increase in the proliferation of RWPE-1 cells, a non-tumorigenic human prostate epithelial cell line ( Figure 5c ). In addition, NT did not stimulate c-Src or EGFR p-Tyr activation in RWPE-1 cells (data not shown). To address these differences between cell lines, NTR1 levels were measured. PC3 and LNCaP cells expressed NTR1, but RWPE-1 had no detectable NTR1 levels ( Figure 5d ). To test the involvement of EGFR and c-Src in this NT response, PC3 cells were incubated with the chemical inhibitors AG1478 or PP2, respectively, during NT incubation. The increase in proliferation observed with a 48 h NT treatment (about twofold) was abolished by either Figure 2 Effect of NT on EGFR tyrosine phosphorylation (p-Tyr) in PC3 cells. Androgen-independent PC3 prostate cancer cells were serum-starved for 48 h and treated with either EGF (100 ng/ml, 5 min) or NT as indicated. Cells were lysed at the end of treatments, and immunoprecipitations were performed using anti-EGFR antibodies as described in Materials and methods. Immunoprecipitated proteins were separated by SDS-PAGE, and Western blotting was performed using antibodies against general p-Tyr or EGFR. Fold-changes in EGFR tyrosine phosphorylation, relative to total EGFR protein in the precipitates, represent the mean of three independent experiments, as calculated by densitometry. *Po0.05, relative to control. (a) Dose dependence of NT using a 60 min incubation (IgG ¼ nonspecific antibody control used for i.p.). (b) Time dependence of NT with a constant 100 nM dose.
(c) Effect of AG1478 (EGFR inhibitor) on NT-induced EGFR phosphorylation. Cells were incubated with 500 nM AG1478 (a) for 1 h before the addition of 100 nM NT (N, 60 min). EGF ¼ 100 ng/ml, 5 min.
AG1478 or PP2 (Figure 6a ). However, incubation with the mitogen-activated protein kinase (MAPK) kinase inhibitor, PD98059, caused no significant decrease in NT-induced proliferation (data not shown). Furthermore, our experiments showed no significant effect of NT on phospho-MAPK levels in PC3 cells (data not shown). Similar results were obtained using DNA synthesis as an end point, as measured by BrdU uptake with flow cytometry (Figure 6b ). Significant increases in both proliferation and DNA synthesis were also observed with EGF (10 ng/ml). SR48692 completely blocked NT-induced mitogenesis of PC3 cells (Figure 6c ), implicating NTR1 in this response. Pre-incubation of PC3 cells with GM1006 for 1 h before and during NT stimulation completely blocked the NT-induced increases in cell proliferation ( Figure 7a ) and DNA synthesis (Figure 7b ). Together, these results implicate a role for NTR1, MMPs, EGFR and c-Src in NT-induced PC3 cell proliferation and DNA synthesis. in NT-induced DNA synthesis. After transient transfection, cells were incubated in the presence or absence of NT (plus trace amounts of serum) for 48 h and analysed by flow cytometry for both EGFR expression and BrdU incorporation. This protocol was used, as adequate expression of these proteins required small amounts of serum present after transfection. Under optimal serum conditions (1% for 18 h, 0.2% for 30 h), cells overexpressing WT EGFR showed a statistically significant (P ¼ 0.009) increase in %BrdU, compared to untreated controls (Figure 8 ). In contrast, no significant increase (P ¼ 0.47) was observed in cells treated with NT when Y845F was overexpressed. A significant increase was demonstrated with NT in cells transfected with the vector control (P ¼ 0.005). Under suboptimal posttransfection serum conditions (10% for 18 h, serum-free for 30 h), significant results were also observed; the P-values for EGFR and Y845F (NT vs control) were 0.02 and 0.71, respectively (data not shown). These results demonstrate that Tyr 845 is critical for the NTinduced increase in DNA synthesis in PC3 cells.
Involvement of Stat5b in NT-induced DNA synthesis
The Stat's are activated by phosphorylation of tyrosine residues in their C-termini and are translocated to the nucleus, where they bind to the promoter regions of genes involved in mitogenesis, differentiation and apoptosis (Schindler and Darnell Jr, 1995; Kloth et al., 2003) . Stat5b has been previously shown to be a mediator of synergism between c-Src and the EGFR and requires EGFR Tyr 845 for its activation (Kloth et al., 2003) . Thus, we examined the role of Stat5b in stimulation of PC3 DNA synthesis by NT. Initial experiments demonstrated a time-dependent increase in endogenous Stat5b tyrosine phosphorylation after NT stimulation of PC3 cells (data not shown). Further experiments were performed by overexpression of Stat5b in PC3 cells, and these experiments were in general agreement with results observed when endogenous protein was examined. Using the overexpression system, NT induced a twofold increase in phosphoStat5b levels, and this increase was blocked by preincubation of cells with AG1478, PP2 (Figure 9a ), or GM6001 (Figure 9b ). To test the involvement of Stat5b in NT-induced DNA synthesis, cells were transfected with either WT Stat5b or a tyrosine mutant of Stat5b (Y699F); expression levels of Stat5b and mutants are shown in Figure 9c . This strategy was employed because Tyr 699 is required for Stat5b-mediated transcriptional activation (Kloth et al., 2002 (Kloth et al., , 2003 . Cells overexpressing WT Stat5b exhibited the characteristic NT-induced increase in %BrdU incorporation; cells transfected with the empty vector also showed a significant increase (P ¼ 0.01) upon NT treatment (Figure 9d ). In contrast, no increase in %BrdU was observed when cells expressing the mutant Stat5b (Y699F) were treated with NT (P ¼ 0.04). To further address the role of Stat5b, a DN form of Stat5b containing a C-terminal truncation was used (Moriggl et al., 1996; Kloth et al., 2003) . Although a sixfold decrease in %BrdU below WT Stat5b levels was observed in cells overexpressing DN-Stat5b, no significant increase was measured with NT treatment (P ¼ 0.78). These results indicate that NT-induced Stat5b phosphorylation involves the EGFR and c-Src and that NT-induced DNA synthesis requires Stat5b activation.
Discussion
These studies were initiated to gain greater mechanistic insights into NE-like cell contributions to progression of prostate cancer (di Sant'Agnese, 1992; Abrahamsson, 1999; Amorino and Parsons, 2004 Our recent work has demonstrated that NE-like cells derived from prostate cancer cells can promote tumorigenesis in vivo (Deeble et al., manuscript in preparation). In this model, D29 cells were co-injected with LNCaP cells subcutaneously into the flanks of nude mice. Following castration, tumors grew significantly faster in the group of mice that were fed dox in their drinking water (to induce NE-like differentiation of D29 cells). The in vitro results with D29 CM shown in Figure 1 support these data and suggest the possibility that the EGFR of prostate cancer cells is involved in the mechanism of growth stimulation in vivo, specifically, through the secretion of paracrine factors by NE cells and transactivation of the EGFR. As AG1478 elicited only a partial inhibition of the growth effect in vitro, however, other factors, such as PTHrP, bombesin, calcitonin and/or serotonin, as well as additional signaling pathways, activated by the neuropeptides may be involved. The finding that SR48692 blocked this effect to the same extent as AG1478 suggests that NT contributes significantly to the PC3 cell proliferation induced by NE-like secretions. However, further work is Cells were serum-starved for 48 h in the presence of 500 nM AG1478, 10 mM PP2 and/or 100 nM NT, and counted at the indicated times. For DNA synthesis measurements, cells were pulse-labeled with BrdU for 2 h, trypsinized, fixed and stained with FITC-anti-BrdU antibodies, and analysed by flow cytometry as described in Materials and methods. Error bars represent the mean of three independent experiments; *Po0.05, relative to control. Preliminary experiments showed a lack of significant involvement of MAPK (p42/42) in NT-induced stimulation of proliferation in PC3 cells. This is consistent with our previous finding that the mitogenic pathway involving Tyr 845 phosphorylation is independent of MAPK activation . Other reports have shown a requirement for MAPK activation in stimulation by neuropeptides of DNA synthesis in Rat-1 fibroblasts (Santiskulvong and Rozengurt, 2003) and prostate cancer cells (Santiskulvong and Rozengurt, 2003; Xiao et al., 2003; Hassan et al., 2004; Hassan and Carraway, 2006) . As we were unable to demonstrate significant activation of MAPK by NT in our system, we postulate that signaling is occurring through an alternative pathway such as that involving Tyr 845 and its downstream effectors (including Stat5b). This conclusion is based upon both data from this study on Tyr 845 and from previous studies in our laboratory on the synergy between c-Src and Tyr 845 in EGFR function of human breast cancer cells and murine fibroblasts . In addition, c-Src has been implicated in NT-induced mitogenesis of LNCaP cells (Lee et al., 2001) .
Involvement of MMPs in EGFR transactivation by GPCRs has been reported previously (Prenzel et al., 1999; Madarame et al., 2003; Santiskulvong and Rozengurt, 2003; Yano et al., 2004; Zhao et al., 2004; Hassan and Carraway, 2006 ). The original model by Ullrich et al. and others (Daub et al., 1996 (Daub et al., , 1997 Prenzel et al., 1999) shows that various GPCR agonists activate GPCRs, resulting in MMP activation either directly or through stimulation of MMP gene expression. The activated MMPs then promote cleavage of membranebound pro-HB-EGF into HB-EGF, which functions as an EGF-like ligand and transactivates the EGFR in an extracellular manner. It has also been proposed that GPCRs can activate the EGFR directly in a c-Srcdependent manner through the heterotrimeric G-protein subunits, G bg (Luttrell et al., 1997) and G a . However, our experiments support the involvement of MMPs, as GM1006 blocks the NT-induced increases in DNA synthesis and proliferation in prostate cancer cells. In addition, we have shown that GM6001 blocks NT-induced activation of EGFR Tyr845, c-Src and Stat5b, which suggests that EGFR transactivation is initiated by MMP activation and not directly through c-Src. Nevertheless, c-Src is still required for Y845 phosphorylation by GPCR agonists (Boerner et al., 2005) . MMPs have been shown to act as early as 5 min and up to 3 h following stimulation to mediate GPCRinduced EGFR transactivation (Prenzel et al., 1999; Santiskulvong and Rozengurt, 2003; Xiao et al., 2003; Hassan and Carraway, 2006) , which is consistent with the kinetics of the response to NT we observe ( Figures  2-4) . The slower kinetics (30-60 min) of NT-mediated EGFR transactivation suggest that gene expression of MMPs may be involved, and that sustained production of MMPs may be important for stimulation of proliferation in this system.
An increase in Stat5b phosphorylation (Tyr 699 ) was observed in cells overexpressing Stat5b, suggesting that endogenous Stat5b is activated by NT. Measurements of endogenous Stat5b were technically difficult (data not shown) owing to low Stat5b protein levels in PC3 cells, but were in reasonable agreement with the results in the overexpressed system. Together, the data shown in Figure 9 are consistent with the conclusion that NT requires Stat5b for induction of DNA synthesis in PC3 cells. Further work is necessary to identify the target genes that are transcriptionally regulated by Stat5b in prostate cancer cells. As inhibition of DNA synthesis was not completely abrogated by mutant Y699F or DN Stat5b, other effectors downstream of Tyr 845 may be involved in the signaling pathway. One possibility is the CoxII, which we have previously demonstrated to bind to EGFR Tyr 845 in breast cancer cells using a phage display screen (Boerner et al., 2004) .
In summary, we have demonstrated that NT induces DNA synthesis and proliferation of human prostate cancer cells in an EGFR-, c-Src, phospho-Tyr 845 -and Stat5b-dependent manner, thereby establishing an important link between neuropeptide growth stimulation of prostate cancer cells and this novel pathway. Furthermore, the molecular effectors identified in these experiments may serve as novel therapeutic targets (especially Tyr 845 ), as NE cells have been implicated in the pathogenesis of late-stage, androgen-independent prostate cancer.
Materials and methods

Reagents
All cell culture medium, FBS, G418 and LipofectAMINE PLUS reagent were obtained from Invitrogen (Carlsbad, CA, USA). Bradford protein assay reagents and broad-range molecular markers were purchased from BioRad (Hercules, CA, USA). BrdU flow kits (including anti-BrdU-fluorescein isothiocyanate (FITC)) and anti-EGFR-phycoerythrin (PE) antibodies were obtained from BD Biosciences (San Diego, CA, USA). Antibodies against phospho-Src (Tyr
419
; also known as Tyr
418
, depending upon the source and reference used), phospho-EGFR (Tyr 845 ) and general phosphotyrosine (PY20) were purchased from Biosource (Camarillo, CA, USA). Antibodies against EGFR and phospho-MAPK (p44/ 42) and anti-rabbit horseradish peroxidase (HRP) secondary antibodies were obtained from Cell Signaling Technology (Beverly, MA, USA). The anti-EGFR antibody (monoclonal antibody (Mab) 108) used for immunoprecipitation was obtained from Dr Michael Weber (University of Virginia (UVA)) (Wright et al., 1996) . The anti-Stat5b antibody was provided by Dr Corinne Silva (UVA) (Kloth et al., 2002) ; antiSrc antibodies were generated by our laboratory . Antibodies specific for phospho-Stat5A/B (Tyr 694/699 ) and protein A agarose beads were purchased from Upstate (Lake Placid, NY, USA). EGF, anti-MAPK (p44/42), anti-FLAG and anti-HA (rabbit) were obtained from Sigma (St Louis, MO, USA); anti-rabbit-PE secondary antibody was purchased from Caltag (Burlingame, CA, USA). The NTR1 antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). NT, PP2, AG1478, GM6001, PD98059, dox and puromycin were purchased from Calbiochem (San Diego, CA, USA). SR48692 was a gift from Sanofi-Aventis (Malvern, PA, USA). CDP-Star (Perkin-Elmer, Wellesley, MA, USA) chemiluminescence kits were used for alkaline phosphatase (AP)-linked secondary antibodies (Promega, Madison, WI, USA); andHRP chemiluminescence kits were obtained from Pierce (Rockford, IL, USA).
Cell culture and treatments PC3 human prostate carcinoma cells, LNCaP human prostate carcinoma cells and RWPE-1 human prostate epithelial cells were obtained from American Type Tissue Collection (ATTC; Rockville, MD, USA). PC3 cells were cultured in DMEM þ 10% FBS þ penicillin-streptomycin (P/S). LNCaP cells were grown in T-medium þ 5% FBS þ P/S. D29 cells (LNCaP with dox-inducible PKA catalytic subunit, see below) were cultured in T-medium þ 5% FBS þ P/S þ 2 mg/ml puromycin þ 600 mg/ml G418. RWPE-1 cells were grown in keratinocyte-serum-free medium þ 0.2 ng/ml EGF þ 25 mg/ml bovine pituitary extract þ P/S. Phenol red-free Rosewell Park Memorial Institute medium (RPMI)-1640 þ P/S þ L-glutamine was used for all serum starvations.
Unless specified otherwise, cells were plated into their respective growth media and incubated at 371C for 24 h, to achieve 25-50% confluency. Cells were then rinsed with phosphate-buffered saline (PBS) and replaced with serum-free medium for 48 h. For proliferation and DNA synthesis experiments, NT and/or inhibitors were added to the medium at the beginning of serum starvation. For Western blotting analysis, cells were treated with NT and/or inhibitors immediately before cell lysis. For experiments involving CM from NE-like cells, D29 cells were plated and incubated in growth medium for 24 h, in the presence or absence of 2 mg/ml dox. Serum-free medium was then added and cells were incubated for an additional 4 days with or without dox. The CM from D29 cells was centrifuged (to remove debris); 25-50% confluent PC3 cells were rinsed and growth medium was replaced with D29 CM for 48 h.
DNA constructs and transfection
Plasmid DNA constructs encoding either HA-tagged WT human Stat5b, a tyrosine mutant of Stat5b (HA-Y699F) or DN HA-tagged Stat5b were provided by Dr Corinne Silva (University of Virginia) and have been described (Kloth et al., 2002) . DN-Stat5b was engineered by inserting a stop codon at amino acid 748 of the WT Stat5b expression plasmid, resulting in a 39-amino-acid C-terminal truncation in the transactivation domain of Stat5b. C-terminally truncated forms of Stat5b have been shown to inhibit transcriptional activation by WT Stat5b (Moriggl et al., 1996) . Construction of a mutant EGFR harboring a phenylalanine substitution for Tyr 845 (Y845F) has been described previously (Boerner et al., 2004) . Appropriate vector DNA for Stat5b (pCMV) or Y845F (pcDNA) experiments were used as negative controls. Four micrograms of each plasmid was transfected into 10-cm dishes of attached PC3 cells using optimum LipofectAMINE PLUS conditions described by the manufacturer. Three hours after transfection in serum-free, antibiotic-free medium, RPMI-1640 þ 1% serum was added ( þ NT, if required), and dishes were incubated at 371C for 18 h. The medium was then changed to RPMI-1640 þ 0.2% serum þ NT (if required), and cells were incubated for another 30 h before BrdU assays.
Immunoprecipitation and Western blotting PC3 cells were cultured as described above. After a 48 h serum starvation, cells were treated with NT and/or inhibitors as indicated in the Results section. Cells were treated with 100 ng/ ml EGF for 5 min as a positive control, unless otherwise indicated. Cells were then immediately rinsed twice with cold PBS, and lysed on ice in CHAPS (3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate) lysis buffer (10 mM CHAPS, 50 mM Tris (pH 8.0), 150 mM NaCl, 2 mM ethylenediaminetetracetic acid) containing protease and tyrosine phosphatase inhibitors (1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM sodium orthovanadate, 17 mg/ml aprotinin and 25 mg/ml leupeptin), and lysates were clarified by centrifugation at 13 000 r.p.m. for 10 min at 41C. Protein was quantitated by using the Bradford assay. For straight lysates, 2 Â sample buffer was added, then samples were boiled for 5 min and stored at À801C. For immunoprecipitation, 1 mg of lysate protein was precleared with 50 ml of protein A agarose beads for 30 min at 41C and incubated with EGFR antibody (MAb 108) or a negative antibody control for 1 h at 41C, with constant rocking. Protein A agarose beads were then added (50 ml), followed by incubation for an additional 30 min at 41C. Immunoprecipitates were washed three times with CHAPS; beads were then resuspended in 2 Â sample buffer, boiled for 5 min, and stored at À801C.
Equal amounts of protein were loaded per lane (100 mg of straight lysates, 1 mg of immunoprecipitate) onto 7.5 or 10% sodium dodecylsulfate (SDS)-polyacrylamide gels. Proteins were electrophoresed and then transferred to nitrocellulose membranes. Antibody incubations were performed as described by the manufacturer. Briefly, membranes were blocked in a solution of 5% non-fat dry milk or 5% bovine serum albumin (for phospho-specific antibodies) in TBS-T (TBS þ 0.1% Tween 20) for 1 h at room temperature. The membrane was then incubated with primary antibodies in either solution listed above (usually 1:1000 dilution) overnight at 41C. Membranes were washed three times for 10 min each with TBS-T and incubated with secondary antibodies (1:2000 for HRP-linked anti-rabbit, 1:5000 for alkaline phosphataselinked anti-mouse) for 1 h. After three more 10 min washes with TBS-T, membranes were subjected to chemiluminescence detection and autoradiography.
Proliferation and DNA synthesis assays Cells were cultured as described above, and serum-starved7 NT for 24, 48 or 72 h (proliferation assays) or 48 h (BrdU assays). For proliferation assays, cells were trypsinized and counted with a hemacytometer. Four grids were counted per sample, and each experiment was repeated three times. Mean cell number was normalized to untreated control values and reported as relative cell number. BrdU assays were performed using BrdU kits as indicated by the manufacturer. Briefly, after serum starvation and treatment with NT7inhibitors or transfections, cells were incubated with 10 mM BrdU for 2 h at 371C. Cells were then trypsinized or scraped (when transfected) and single-cell suspensions were generated. After two PBS rinses, cells were incubated with anti-EGFR-PE for 45 min (if EGFR or Y845F was transfected), rinsed and stored overnight at 41C. On the day of analysis, cells were fixed twice with paraformaldehyde on ice (30 min total), treated with 300 mg/ml DNAase for 1 h at 371C and incubated with FITCconjugated anti-BrdU antibodies ( þ rabbit anti-HA if HAStat5b, HA-Y699F or HA-DN-Stat5b was transfected) for 20 min. After rinsing, cells were incubated with PE-conjugated anti-rabbit for 30 min, resuspended in staining buffer and analysed using a FACS-Caliber flow cytometer (BectonDickinson, Franklin Lakes, NJ, USA). Twenty thosand cells were analysed per sample; %BrdU histograms were gated on PE-positive cells, corresponding to either EGFR or HA (Stat5b or mutants). Data analysis was performed using Flow-Jo software, at the UVA Flow Cytometry Core Facility D29 cell line NE differentiation of LNCaP cells by expression of a constitutively active PKA catalytic subunit (Cqr) has been described previously (Cox et al., 2000) (also Deeble et al., manuscript in preparation) . Briefly, to generate dox-inducible expression vectors for Cqr, the Clontech (Palo Alto, CA, USA) Tet-On gene expression system was used. Plasmids encoding a constitutively active mutant (Cqr) of the PKA catalytic subunit (CIa) were a gift from Dr GS McKnight (University of Washington, Seattle) (Orellana and McKnight, 1992) . Cqr subunits were amino terminally FLAG-tagged and subcloned into the pTRE vector. The p-Tet-On vector, which contains a neomycin marker (and, thus, confers resistance to G418), encodes the regulatory protein rtTA. In the presence of dox, rtTA binds the tetracycline response element (TRE) of pTRE and activates transcription of Cqr.
LNCaP cells were stably transfected with pTet-On and selected using 600 mg/ml G418. Screening of clones was performed by transfection of a luciferase reporter plasmid, pTRE-Luc, followed by treatment with 1 mg/ml dox and measurement of induction of luciferase expression. A positive clone that yielded the highest dox-induced luciferase activity and the lowest constitutive activity (in the absence of dox) was then co-transfected with pTRE-FLAG Cqr and pTK-Puro at a 5:1 ratio and selected with 2 mg/ml puromycin. Clones were screened by Western blotting using an anti-FLAG antibody, as well as by microscopy to examine NE characteristics as described previously . A clone with optimal dox-inducible Cqr expression and dox-inducible NE differentiation was selected and denoted as D29.
Statistical analysis
All error bars represent the standard error of the mean from N ¼ 3 independent experiments, unless indicated. P-values were obtained using a Student's t-test (Sigma-Plot); P-values less than 0.05 were considered statistically significant.
